New therapeutic options for advanced thyroid cancer;Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 22, 2011, Pages 1165-1168

  Willhauck, M J ^a   Schott, M ^b   Kreissl, M C ^c   Fassnacht, M ^c   Spitzweg, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

multi tyrosine kinase inhibitors; sorafenib; sunitinib; thyroid cancer; vandetanib

Indexed keywords

ADVANCED CANCER; NOTE; THYROID CANCER;

EID: 79957574970     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1280531     Document Type: Note

References (17)

1. Bible K C., Suman V J., Molina J R. et al,. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers. Lancet Oncol 2010 11 962-972
2. Carr L L., Mankoff D A., Goulart B H. et al,. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010 16 5260-5268
3. Cohen E EW, Needles B M., Cullen K J. et al,. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008 26 (Suppl.) Abstract 6025
4. Cohen E EW, Rosen L S., Vokes E E. et al,. Axitinib is an active traetment for all histologic subtypes of advanced thyroid cancer. J Clin Oncol 2008 26 4708-4713
5. De Souza J A., Busaidy N, Zimrin A et al,. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010 28 (Suppl.) Abstract 5504
6. Gupta-Abramson V, Troxel A B., Nellore A et al,. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008 26 4714-4719
7. Hoftijzer H, Heemastra K A., Morreau H et al,. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009 161 923-931
8. Kloos R T., Ringel M D., Knopp M V. et al,. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009 27 1675-1684
9. Kurzrock R, Cohen E E., Sherman S I. et al,. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL 184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010 28 (Suppl.) Abstract 5502
10. Lam E T., Ringel M D., Kloos R T. et al,. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010 28 2323-2330
11. Ravaud A, de la Fouchardiere C, Courbon F et al,. Sunitinib in patients with refractory advanced thyroid cancer. J Clin Oncol 2008 26 Suppl Abstract 6058
12. Robinson B G., Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010 95 2664-2671
13. Schlumberger M, Elisei R, Bastholt L et al,. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009 27 3794-3801
14. Sherman S I., Wirth L J., Droz J -P et al,. Motesanib diphosphate in progressive differentiated thyroid cancer. New Engl J Med 2008 359 31-42 (Pubitemid 351931094)
15. Wells S A., Gosnell J E., Gagel R F. et al,. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010 28 767-772
16. Wells S A., Robinson B G., Gagel R F. et al,. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC). J Clin Oncol 2010 28 (Suppl.) Abstract 5503
17. Woyach J A., Shah M H. New therapeutic advances in the management of progressive thyroid cancer. Endocrine Rel Cancer 2009 16 715-731